Friday 6 November 2026 Export BBIO’s income statement to Excel — free account

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.

Revenue: +192.6%
EPS: +67.5%
Free cash flow: +60.5%
Total debt: +4.21%

Quarter to September 2026, against a year earlier

74.28 0.01 +0.01%

Follow BBIO

Alert me

Market cap: $14.5B
P/E: 0.0×
Fwd P/E: −27.5×
Dividend yield: —
F-score: 3/9
Altman Z: −3.45
Beneish M: 8.17
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

BridgeBio Pharma, Inc. 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Oct 29, 2026 · accepted 4:52 PM ET · Document on sec.gov · Filing index

Red flags

Receivables outpacing revenue Oct 29, 2026
Receivables grew 221.9% while revenue grew 192.6% year over year

10-Q filed Oct 29, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Oct 29, 2025: 28 added · 30 removed · 59 modified; 5 with only figures updated; 12 moved without change

BridgeBio Pharma, Inc. 10-Q filed Oct 29, 2026

Red flags

What changed

Stockrow Weekly